Skip to main content

Table 2 Change in radicular pain at days 0 and 10 after injection

From: Tumor necrosis factor-α blockade in recurrent and disabling chronic sciatica associated with post-operative peridural lumbar fibrosis: results of a double-blind, placebo randomized controlled study

Outcomes IFX group Placebo group All patients p-value
n = 18 n = 17 n = 35
Day 0 after injection
 Absolute VAS change, median (IQR) −26.8 (–54.8 to –14.3) −56.7 (–73.3 to –28.6) −36.0 (–72.3 to –14.3) 0.22
 50 % reduction in sciatica pain, n (%) 5 (27.8) 9 (52.9) 14 (40.0) 0.13
 PASS <40 mm, n (%) 5 (27.8) 12 (70.6) 17 (48.6) 0.01*
 MCII ≥15 mm, n (%) 12 (66.7) 13 (76.5) 25 (71.4) 0.52
 MCII ≥20 %, n (%) 11 (61.1) 13 (76.5) 24 (68.6) 0.33
Day 10 after injection
 Absolute VAS change, median (IQR) −14.9 (–50.0 to 3.3) 0.0 (–30.9 to 10.0) −9.2 (–38.5 to 9.1) 0.21
 50 % reduction in sciatica pain, n (%) 5 (27.8) 3 (17.6) 8 (22.9) 0.69
 PASS <40 mm, n (%) 4 (22.2) 4 (23.5) 8 (22.9) 0.94
 MCII ≥15 mm, n (%) 9 (50.0) 5 (29.4) 14 (40.0) 0.21
 MCII ≥20 %, n (%) 8 (44.4) 5 (29.4) 13 (37.1) 0.36
  1. *p <0.05 comparing IFX and placebo groups by Wilcoxon Mann-Whitney test for quantitative variables and Fisher’s exact test for qualitative variables
  2. IFX Infliximab, IQR Interquartile range, MCII Minimum Clinically Important Improvement, n Absolute frequency, PASS Patient Acceptable Symptom State, VAS Visual analog scale